Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon.
BACKGROUND
The aim of this study is to determine the prevalence of anti-HCV among injecting drug users (IDUs) in Lebanon, to establish the current prevalence of HCV genotypes in this population and to determine whether demographic characteristics and behavioral variables differ between participants who were HCV-RNA positive and those who were HCV-RNA negative or between the different genotypes. Participants were recruited using respondent-driven sampling method. The blood samples were collected as dried blood spots and then eluted to be tested for HCV, HBV and HIV by ELISA. Anti-HCV positive samples were subjected to RNA extraction followed by qualitative detection and genotyping.


RESULTS
Among 106 IDUs, 56 (52.8%) were anti-HCV-positive. The two groups did not differ in terms of age, marital status, and nationality. As for the behavioral variable, there was a trend of increased risky behaviors among the HCV-RNA positive group as compared to the HCV-RNA negative group but none of the variables reached statistical significance. Half (50%) of the 56 anti-HCV-positive were HCV-RNA positive. Genotype 3 was the predominant one (57.1%) followed by genotype 1 (21%) and genotype 4 (18%).


CONCLUSIONS
The predominance of genotype 3 seems to be the predominant genotype among IDUs in Lebanon, a situation similar to that among IDUs in Western Europe. This study provides a base-line against possible future radical epidemiological variant that might occur in IDUs.
Mahfoud
Ziyad
Z
Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
Kassak
Kassem
K
Kreidieh
Khalil
K
Shamra
Sarah
S
Ramia
Sami
S
D000328:Adult; D055030:Drug Users; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics* / Q000302:isolation & purification; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology / Q000821:virology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007861:Lebanon / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D018937:Hepatitis C Antibodies
Int J Drug Policy. 2007 Oct;18(5):359-63
17854723
Gastroenterol Clin Biol. 2007 May;31(5):480-4
17541337
J Gen Virol. 1996 Feb;77 ( Pt 2 ):293-301
8627233
J Hepatol. 1995 Jun;22(6):691-5
7560863
J Clin Pathol. 1999 Sep;52(9):633-9
10655983
Epidemiol Infect. 2007 Apr;135(3):427-32
16848924
Eur J Clin Microbiol Infect Dis. 2005 Aug;24(8):514-22
16133411
Med J Aust. 2000 Jun 19;172(12):588-91
10914104
J Infect. 2000 Mar;40(2):176-83
10841096
N Engl J Med. 2001 Jul 5;345(1):41-52
11439948
Scand J Infect Dis. 2001;33(6):457-61
11450866
J Infect Dis. 1995 Jun;171(6):1607-10
7769300
J Gen Virol. 1997 Jan;78 ( Pt 1):45-51
9010284
J Infect Dis. 2001 Sep 1;184(5):659-60
11494175
J Med Virol. 2008 Apr;80(4):640-5
18297717
Lancet. 2003 Dec 20;362(9401):2095-100
14697814
J Med Virol. 2008 Apr;80(4):603-6
18297713
J Med Virol. 2003 Mar;69(3):367-75
12526047
Infect Genet Evol. 2005 Mar;5(2):131-9
15639745
J Gen Virol. 1995 Sep;76 ( Pt 9):2329-35
7561773